Identifying Patients at High Risk of Myeloid Neoplasms After CAR T: Implications for Care, Surveillance
For chimeric antigen receptor T-cell therapies (CAR T) approved to treat B-cell lymphoproliferative disorders and multiple myeloma, more data are needed on the effects of posttreatment myeloid neoplasms to optimize patient counseling, risk stratification, and surveillance.
Source: ajmc.com